SYNOPSIS Platelet survival has been measured in 16 patients with idiopathic thrombocytopenic purpura. Of this group, three patients had a normal result and surface counting did not show high spienic uptake. The clinical features of these patients are described. These patients have remained well for several years without treatment.
The diagnosis of idiopathic thrombocytopenic purpura is made when a low platelet count is associated with normal or increased numbers of megakaryocytes in an otherwise normal bone marrow and the patient gives no history of exposure to drugs or chemicals, shows no evidence of systemic disease, and little or no splenic enlargement.
The cause is uncertain, but present evidence suggests that many cases may have an autoimmune basis. Platelet antibodies or platelet sensitization (Moulinier, 1955; van de Wiel, Dorfmeyer, and van Loghem, 1961) or megakaryocyte antibodies (McKenna and Pisciotta, 1962) can be demonstrated in a high proportion of patients and the majority respond to corticosteroid therapy, at least for a time. There have also been reports of remission on treatment with other immunosuppressive agents (Richmond, Woodruff, Cumming, and Donald, 1963; Martin, Nowicki, Schubert, and Schubert, 1967) . In addition an analogous condition may be associated with other disorders believed to be autoimmune in nature such as disseminated lupus erythematosus and autoimmune haemolytic anaemia. Harrington, Minnich, Hollingsworth, and Moore (1951) showed that transfusion of blood or plasma from patients with idiopathic thrombocytopenic purpura into normal recipients resulted in thrombocytopenia in 60% of cases studied. Harrington, Sprague, Minnich, Moore, Aulvin, and Dubach (1953) showed further that the thrombocytopenic effect of patient's plasma was diminished in the absence of the spleen. It has recently been demonstrated that this plasma factor is present in the IgC globulin fraction and is species specific (Shulman, Marder, and Weinrach, 1964) . The precise mechanism of production of the thrombocytopenia is uncertain but measurements with radioisotope-labelled platelets favour reduction of the platelet survival time in the peripheral circulation in the majority of patients, with uptake of the labelled platelets predominantly in the spleen or the liver. In the studies of Najean, Ardaillou, Dresch, and Bernard (1967) and Aster and Keene (1969) those patients showing high hepatic sequestration of the platelets were the ones who responded poorly to splenectomy.
In some studies of platelet survival in idiopathic thrombocytopenic purpura there have been occasional patients in whom the platelet life span has been normal. While Najean and his colleagues encountered none in a series of 85 patients, Cohen, Gardner, and Bamett (1961) observed this in four of their patients and Aster and Jandl (1964) in one of their patients.
In studies of various platelet disorders using radioactive chromium (5'Cr) as a platelet label, three individuals in a series of 16 patients with an initial diagnosis of idiopathic thrombocytopenic purpura have been encountered who showed normal platelet survival and it is the purpose of the present paper to draw attention to this atypical group.
Methods
The 16 patients considered to have the disorder ranged in age from 7 to 70 years. Seven were males and nine females. In four patients splenectomy has been undertaken without effect.
Routine haematological measurements were made using the techniques described by Dacie and Lewis (1968) . Detection of platelet antibodies was by the technique of Dausset, Colombani, and Colombani 621 (1961) and of megakaryocyte antibodies by the method of Coons (1958 In an attempt to standardize the results for all patients and to assess the amount of radioactivity in the spleen, the surface counts over the spleen at day 1 or at 50% of the extinction time, whichever was the longer, were corrected for decay and divided by the total amount of injected platelet-bound radioactivity in microcuries (Aster and Jandl, 1964) . This is an arbitrary value, the results of which depend amongst other factors on the counting system employed. The equipment used in this study gave 18 counts/second/microcurie at a distance of 10 cm from the crystal, with a background of 11 counts/ second.
In order to determine platelet-bound radioactivity, two 1 ml aliquots of the platelet infusion were taken. One was diluted in 200 ml of water. The The results of platelet survival measurements are given in the Table. It will be seen that 13 patients showed a shortened platelet survival time but three patients (nos. 10, 11, and 12) were found to have a result within the normal range (8-11 days).
Platelet survival curves for the patients described in this paper are shown in Figure 1 . The radioactivity falls in a curvilinear fashion and becomes negligible in eight to 11 days.
The data used to assess the spleen and liver uptake of radioactivity are given in Figures 2 and 3 This girl, aged 7 years, was first seen in May 1963 on account of recurrent epistaxes for the previous three years. Physical examination was entirely negative. The peripheral blood picture showed iron-deficiency anaemia and thrombocytopenia: Hb was 9-5 g, PCV 27, MCHC 28-5 reticulocytes 4-5 %, WCC 7,300, platelets 40,000. Marrow examination revealed an increased number of megakaryocytes, but was otherwise normal. The Coombs test was negative and platelet antibodies could not be detected. The platelet survival measurement was normal to six days when it had to be interrupted on account of epistaxis; however, extrapolation of the disappearance curve gave an extinction time of eight days.
The child received corticosteroid therapy in the form of prednisone starting in a dose of 30 mg per day. This was continued in reducing amounts for five months. There was no significant effect on the platelet count, the maximum level reached being 65,000 per cmm.
In the intervening period, the patient has remained relatively well apart from occasional epistaxis. At a recent review (in May, 1970) 
Comment
In series of patients with apparent idiopathic thrombocytopenic purpura there are small numbers who differ from the majority by showing a normal platelet survival time. The three cases in the present study did not show high splenic uptake of labelled platelets and the most likely explanation would appear to be a production deficit. However, with present techniques, no megakaryocyte antibody could be demonstrated in the two patients where this was tested.
None of the patients proceeded to splenectomy and it is therefore not known what effect surgery would have in this atypical group; it is interesting, however, that two showed no significant response to corticosteroid therapy, the third (no. 12) responded initially. These three patients have remained well over several years without treatment.
